Benefits
Symptomatic Support in Mild–Moderate Dementia
In established mild-to-moderate dementia, the standardized 240 mg/day extract has shown improvements in cognition, daily function, and global clinical ratings versus placebo across multiple controlled trials and dedicated meta-analyses. The signal is for symptomatic support of existing dementia, not disease prevention or modification.
Behavioral & Neuropsychiatric Symptoms
The strongest and most consistent effect appears in dementia accompanied by neuropsychiatric symptoms such as apathy, anxiety, irritability, and depressed mood. Standardized extract may help reduce these behavioral symptoms and ease caregiver burden, with benefits measured on neuropsychiatric inventory scales.
Generalized Anxiety Symptoms
Studied for generalized anxiety and adjustment disorder with anxious mood, the standardized extract has reduced anxiety rating-scale scores versus placebo over several weeks, with a dose-related trend favoring higher intakes. Considered a complementary option rather than a replacement for established anxiety care.
Antioxidant & Microcirculatory Support
The standardized flavonoid and terpene-lactone profile supports antioxidant defense and healthy microcirculation. Ginkgolides modulate platelet-activating factor and the extract may promote vasodilation, which underlies its traditional use for cerebral and peripheral blood flow.
Mechanism of action
Platelet-Activating Factor Inhibition & Microcirculation
Ginkgolides, particularly ginkgolide B, antagonize platelet-activating factor (PAF), reducing platelet aggregation and blood viscosity while promoting nitric-oxide-mediated vasodilation. This enhances cerebral and peripheral microcirculation and contributes to the bleeding-risk interaction profile.
Antioxidant / Free-Radical Scavenging
Flavonol glycosides (quercetin, kaempferol, isorhamnetin) scavenge reactive oxygen species and chelate pro-oxidant metals, protecting neurons and vascular endothelium from oxidative stress implicated in vascular and neurodegenerative aging.
Neuroprotection & Mitochondrial Stabilization
Bilobalide stabilizes mitochondrial membranes, supports ATP production, and may attenuate glutamate excitotoxicity and apoptosis under hypoxic or ischemic stress, supporting neuronal resilience in compromised brain tissue.
Neurotransmitter Modulation
The extract influences cholinergic, serotonergic, and dopaminergic signaling and may modestly inhibit monoamine oxidase, mechanisms thought to underlie its measured effects on mood, anxiety, and cognitive processing in clinical studies.
Clinical trials
Placebo-controlled, double-blind, randomized trial in 309 patients with mild-to-severe Alzheimer's disease or multi-infarct dementia receiving EGb 761 120 mg/day vs placebo for 52 weeks (North American EGb Study Group).
309 patients with Alzheimer's or multi-infarct dementia. 52-week intervention.
EGb 761 produced a small but statistically significant benefit versus placebo on the ADAS-Cog and caregiver-rated GERRI; clinician global impression did not differ. A modest effect, but the influential early trial that established EGb 761 as the reference ginkgo extract in dementia research.
Ginkgo Evaluation of Memory Study: randomized, double-blind, placebo-controlled trial in 3,069 community-dwelling adults aged 75+ with normal cognition or mild cognitive impairment receiving EGb 761 240 mg/day vs placebo. Median follow-up ~6 years.
3,069 older adults aged 75+. ~6-year follow-up.
PRIMARY ENDPOINT NEGATIVE: EGb 761 did not significantly reduce the incidence of all-cause dementia or Alzheimer's disease versus placebo. A large, definitive trial that substantially weakened the case for ginkgo as a dementia-prevention agent.
Randomized, double-blind, placebo-controlled trial in 2,854 adults aged 70+ with spontaneous memory complaints receiving EGb 761 240 mg/day vs placebo for 5 years.
2,854 older adults with memory complaints. 5-year intervention.
PRIMARY ENDPOINT NEGATIVE: EGb 761 did not significantly reduce progression to Alzheimer's disease versus placebo on intention-to-treat analysis. Together with GEM, two large multi-year trials confirm ginkgo does not prevent dementia.
24-week randomized, double-blind, placebo-controlled trial in 410 patients with mild-to-moderate Alzheimer's or vascular dementia plus neuropsychiatric symptoms, receiving EGb 761 240 mg once daily vs placebo.
410 dementia patients with neuropsychiatric symptoms. 24-week intervention.
POSITIVE: EGb 761 240 mg/day produced significant, clinically relevant improvement versus placebo on cognition (SKT), neuropsychiatric symptoms (NPI), and functional/quality-of-life measures. Represents the indication where EGb 761's evidence is strongest.
Two systematic reviews pooling placebo-controlled EGb 761 trials in dementia: an industry-affiliated meta-analysis (7 RCTs, ~2,625 patients) and an independent meta-analysis (9 RCTs, ~2,561 patients).
Pooled dementia/cognitive-impairment patients across 7–9 RCTs.
Both found EGb 761 240 mg/day can stabilize or slow decline in cognition, function, behavior, and global change at 22–26 weeks, with tolerability similar to placebo. The independent analysis noted the benefit was clearest in patients WITH neuropsychiatric symptoms and not statistically superior in the Alzheimer's-only subgroup.